NO20004363L - Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme - Google Patents

Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme

Info

Publication number
NO20004363L
NO20004363L NO20004363A NO20004363A NO20004363L NO 20004363 L NO20004363 L NO 20004363L NO 20004363 A NO20004363 A NO 20004363A NO 20004363 A NO20004363 A NO 20004363A NO 20004363 L NO20004363 L NO 20004363L
Authority
NO
Norway
Prior art keywords
disorders
autism
obsessive
antagonists
treatment
Prior art date
Application number
NO20004363A
Other languages
English (en)
Other versions
NO20004363D0 (no
Inventor
Vicki L Coffin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20004363D0 publication Critical patent/NO20004363D0/no
Publication of NO20004363L publication Critical patent/NO20004363L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Fremgangsmåte for å behandle tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, spiseforstyrrelser, impulskontrollforstyrrelser og autisme er beskrevet. Disse forstyrrelser behandles ved å administrere en effektiv mengde av en Dl-/D5-antagonist.
NO20004363A 1998-03-02 2000-09-01 Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme NO20004363L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3320598A 1998-03-02 1998-03-02
PCT/US1999/003721 WO1999044615A1 (en) 1998-03-02 1999-03-01 Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism

Publications (2)

Publication Number Publication Date
NO20004363D0 NO20004363D0 (no) 2000-09-01
NO20004363L true NO20004363L (no) 2000-10-31

Family

ID=21869083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004363A NO20004363L (no) 1998-03-02 2000-09-01 Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme

Country Status (16)

Country Link
EP (1) EP1058551A1 (no)
JP (1) JP2002505291A (no)
KR (1) KR20010041477A (no)
CN (1) CN1291893A (no)
AR (1) AR018297A1 (no)
AU (1) AU2778099A (no)
BR (1) BR9908392A (no)
CA (1) CA2322201A1 (no)
CO (1) CO4910136A1 (no)
HU (1) HUP0101057A3 (no)
IL (1) IL137715A0 (no)
NO (1) NO20004363L (no)
PE (1) PE20000333A1 (no)
SK (1) SK12962000A3 (no)
WO (1) WO1999044615A1 (no)
ZA (1) ZA991638B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
RU2374245C1 (ru) 2008-08-22 2009-11-27 Андрей Александрович Иващенко Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство
HRP20220701T1 (hr) * 2012-07-12 2022-07-08 Emalex Biosciences, Inc. Spojeni benzazepini za liječenje touretteova sindroma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
CO4970824A1 (es) * 1997-10-28 2000-11-07 Schering Corp Metodo para reducir las ansias de consumo en mamiferos

Also Published As

Publication number Publication date
ZA991638B (en) 1999-09-01
HUP0101057A3 (en) 2001-09-28
NO20004363D0 (no) 2000-09-01
BR9908392A (pt) 2000-10-31
WO1999044615A1 (en) 1999-09-10
SK12962000A3 (sk) 2001-08-06
JP2002505291A (ja) 2002-02-19
PE20000333A1 (es) 2000-05-13
IL137715A0 (en) 2001-10-31
AR018297A1 (es) 2001-11-14
CA2322201A1 (en) 1999-09-10
KR20010041477A (ko) 2001-05-25
HUP0101057A2 (hu) 2001-08-28
AU2778099A (en) 1999-09-20
CO4910136A1 (es) 2000-04-24
EP1058551A1 (en) 2000-12-13
CN1291893A (zh) 2001-04-18

Similar Documents

Publication Publication Date Title
ATE515513T1 (de) Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
ATE364386T1 (de) (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
MY169308A (en) Treatment of tnf? related disorders
ATE526959T1 (de) Behandlung von muskelschwund mit selektiven androgenrezeptormodulatoren
WO2000043032A3 (en) Baff, inhibitors thereof and their use in the modulation of b-cell response
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE359076T1 (de) Mittel gegen juckreiz
IL148071A0 (en) Method for treatment of symptoms of central nervous system disorders
PL346876A1 (en) Mglur5 antagonists for the treatment of pain and anxiety
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
MXPA01001535A (es) Dispositivo para irradiacion untravioleta para el tratamiento de aguas residuales.
PL1608685T3 (pl) Antagoniści VEGF do leczenia cukrzycy
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
EP1419236A4 (en) METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
NO20004363L (no) Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
DE60124791D1 (de) S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen.
EP1581759A4 (en) METHODS OF TREATING TAXOL INDUCED SENSORY NEUROPATHY
AU2003282035A1 (en) Modulation of s6 kinase activity for the treatment of obestiy
SG121787A1 (en) Oil retention treatment agent, oil retention treatment method using the same, and watch having been oil retention treated by the oil retention treatment method